R&D Pipeline
Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.
Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.
Therapeutic Area
Condition/Disease
Agents
Mechanism
Phase
Partner
Hematological Cancer
Large B-Cell Lymphoma
Large B-Cell Lymphoma
Solid Tumors
Maintenance Bladder Cancer
Maintenance Bladder Cancer
Agent(s)
NKTR-255 + Bavencio®
Mechanism
IL-15 Receptor Agonist + PD-L1 Inhibitor
Partner
NCT#
NCT05327530
Solid Tumors
Stage 2 Non-small Cell Lung Cancer Post Chemoradiation
Stage 2 Non-small Cell Lung Cancer Post Chemoradiation
Hematological Cancer
Relapsed/Refractory Large B Cell Lymphoma
Relapsed/Refractory Large B Cell Lymphoma
Hematological Cancer
B-Cell Acute Lymphoblastic Leukemia
B-Cell Acute Lymphoblastic Leukemia
Autoimmune Disorders
Atopic Dermatitis
Atopic Dermatitis
Autoimmune Disorders
Autoimmune Disorders
Immuno-Oncology
